Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
Nuclear Medicine Communications 2023 March 11
PURPOSE: Rarely, well-differentiated gastro-entero-pancreatic neuroendocrine tumors (GEP NETs) can have positive uptake on 18F-fluorodeoxyglucose-PET/computerized tomography (18F-FDG-PET/CT), with or without a positive 68Ga-PET/CT. We aim to evaluate the diagnostic role of 18F-FDG-PET/CT in patients with well-differentiated GEP NETs.
METHODS: We retrospectively reviewed a chart of patients diagnosed with GEP NETs between 2014 and 2021, at the American University of Beirut Medical Center, who have low (G1; Ki-67 ≤2) or intermediate (G2; and Ki-67 >2-≤20) well-differentiated tumors with positive findings on FDG-PET/CT. The primary endpoint is progression-free survival (PFS) compared to historical control, and the secondary outcome is to describe their clinical outcome.
RESULTS: In total 8 out of 36 patients with G1 or G2 GEP NET met the inclusion criteria for this study. The median age was 60 years (range 51-75 years) and 75% were male. One patient (12.5%) had a G1 tumor whereas 7 (87.5%) had G2, and seven patients were stage IV. The primary tumor was intestinal in 62.5% of the patients and pancreatic in 37.5%. Seven patients had both 18F-FDG-PET/CT and 68Ga-PET/CT positive and one patient had a positive 18F-FDG-PET/CT and negative 68Ga-PET/CT. Median and mean PFS in patients positive for both 68Ga-PET/CT and 18F-FDG-PET/CT were 49.71 months and 37.5 months (95% CI, 20.7-54.3), respectively. PFS in these patients is lower than that reported in the literature for G1/G2 NETs with positive 68Ga-PET/CT and negative FDG-PET/CT (37.5 vs. 71 months; P = 0.0217).
CONCLUSION: A new prognostic score that includes 18F-FDG-PET/CT in G1/G2 GEP NETs could identify more aggressive tumors.
METHODS: We retrospectively reviewed a chart of patients diagnosed with GEP NETs between 2014 and 2021, at the American University of Beirut Medical Center, who have low (G1; Ki-67 ≤2) or intermediate (G2; and Ki-67 >2-≤20) well-differentiated tumors with positive findings on FDG-PET/CT. The primary endpoint is progression-free survival (PFS) compared to historical control, and the secondary outcome is to describe their clinical outcome.
RESULTS: In total 8 out of 36 patients with G1 or G2 GEP NET met the inclusion criteria for this study. The median age was 60 years (range 51-75 years) and 75% were male. One patient (12.5%) had a G1 tumor whereas 7 (87.5%) had G2, and seven patients were stage IV. The primary tumor was intestinal in 62.5% of the patients and pancreatic in 37.5%. Seven patients had both 18F-FDG-PET/CT and 68Ga-PET/CT positive and one patient had a positive 18F-FDG-PET/CT and negative 68Ga-PET/CT. Median and mean PFS in patients positive for both 68Ga-PET/CT and 18F-FDG-PET/CT were 49.71 months and 37.5 months (95% CI, 20.7-54.3), respectively. PFS in these patients is lower than that reported in the literature for G1/G2 NETs with positive 68Ga-PET/CT and negative FDG-PET/CT (37.5 vs. 71 months; P = 0.0217).
CONCLUSION: A new prognostic score that includes 18F-FDG-PET/CT in G1/G2 GEP NETs could identify more aggressive tumors.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app